Progress and value of radiotherapy for non-small cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2019.04.012

Abstract

Abstract: With the innovation of radiotherapy equipment and the promotion of targeted therapy and immunotherapy, the therapeutic mode and status of radiotherapy in non-small cell lung cancer (NSCLC) are constantly changing. For early NSCLC, stereotactic radiotherapy may be an alternative to surgery, but the optimal segmentation model still needs to be explored. As for locally advanced NSCLC, postoperative radiotherapy is still controversial for operable patients, the results of consolidated immunotherapy after concurrent chemoradiotherapy in inoperable patients are encouraging, prophylactic cranial irradiation does not improve survival. Local radiotherapy for patients with oligometastasis is expected to prolong survival.

Key words: Carcinoma, non-small-cell lung, Radiotherapy, Treatment outcome, Prognosis

Gao Zhao, Yan Wenxing, Liu Linlin. Progress and value of radiotherapy for non-small cell lung cancer[J]. Journal of International Oncology, 2019, 46(4): 248-252.

References

［1］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018［J］. CA Cancer J Clin, 2018, 68(1): 7-30. DOI: 10.3322/caac.21442. ［2］ Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study［J］. JAMA Oncol, 2017, 3(4): 524-548. DOI: 10.1001/jamaoncol.2016.5688. ［3］ Bristow RG, Alexander B, Baumann M, et al. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology［J］. Lancet Oncol, 2018, 19(5): e240-e251. DOI: 10.1016/S1470-2045(18)30096-2. ［4］ Timmerman RD, Hu C, Michalski JM, et al. Long-term results of stereotactic body radiation therapy in medically inoperable stage Ⅰ non-small cell lung cancer［J］. JAMA Oncol, 2018, 4(9): 1287-1288. DOI: 10.1001/jamaoncol.2018.1258. ［5］ Timmerman RD, Paulus R, Pass HI, et al. Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG oncology RTOG 0618 trial［J］. JAMA Oncol, 2018, 4(9): 1263-1266. DOI: 10.1001/jamaoncol.2018.1251. ［6］ Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non-small-cell lung cancer: a pooled analysis of two randomised trials［J］. Lancet Oncol, 2015, 16(6): 630-637. DOI: 10.1016/S1470-2045(15)70168-3. ［7］ Nagata Y, Hiraoka M, Shibata T, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403［J］. Int J Radiat Oncol Biol Phys, 2015, 93(5): 989-996. DOI: 10.1016/j.ijrobp.2015.07.2278. ［8］ Videtic GM, Paulus R, Singh AK, et al. Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage Ⅰ peripheral non-small cell lung cancer［J］. Int J Radiat Oncol Biol Phys, 2019, 103(5): 1077-1084. DOI: 10.1016/j.ijrobp.2018.11.051. ［9］ Nyman J, Hallqvist A, Lund JA, et al. SPACE-A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage Ⅰ NSCLC［J］. Radiother Oncol, 2016, 121(1): 1-8. DOI: 10.1016/j.radonc.2016.08.015. ［10］ Haque W, Verma V, Polamraju P, et al. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage nonsmall cell lung cancer［J］. Radiother Oncol, 2018, 129(2): 264-269. DOI: 10.1016/j.radonc.2018.07.008. ［11］ Stam B, Kwint M, Guckenberger M, et al. Subgroup survival analysis in stage Ⅰ-Ⅱ NSCLC patients with a central tumor partly treated with risk-adapted SBRT［J］. Int J Radiat Oncol Biol Phys, 2019, 103(1): 132-141. DOI: 10.1016/j.ijrobp.2018.08.040. ［12］ Roach MC, Robinson CG, DeWees TA, et al. Stereotactic body radiation therapy for central early-stage NSCLC: results of a prospective phase Ⅰ/Ⅱ trial［J］. J Thorac Oncol, 2018, 13(11): 1727-1732. DOI: 10.1016/j.jtho.2018.07.017. ［13］ Burdett S, Pignon JP, Tierney J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer［J］. Cochrane Database Syst Rev, 2015, (3): CD011430. DOI: 10.1002/14651858.CD011430. ［14］ Murakami S, Saito H, Kondo T, et al. Phase Ⅱ study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer［J］. Cancer Chemother Pharmacol, 2018, 81(1): 81-87. DOI: 10.1007/s00280-017-3460-0. ［15］ Burdett S, Rydzewska L, Tierney J, et al. Postoperative radiotherapy for non-small cell lung cancer［J］. Cochrane Database Syst Rev, 2016, 10: CD002142. DOI: 10.1002/14651858.CD002142.pub4. ［16］ Robinson CG, Patel AP, Bradley JD, et al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base［J］. J Clin Oncol, 2015, 33(8): 870-876. DOI: 10.1200/JCO.2014.58.5380. ［17］ Wang EH, Corso CD, Rutter CE, et al. Postoperative radiation therapy is associated with improved overall survival in incompletely resected stage Ⅱ and Ⅲ non-small-cell lung cancer［J］. J Clin Oncol, 2015, 33(25): 2727-2734. DOI: 10.1200/JCO.2015.61.1517. ［18］ Herskovic A, Mauer E, Christos P , et al. Role of postoperative radiotherapy in pathologic stage ⅢA (N2) non-small cell lung cancer in a prospective nationwide oncology outcomes database［J］. J Thorac Oncol, 2017, 12(2): 302-313. DOI: 10.1016/j.jtho.2016.09.135. ［19］ Hui Z, Men Y, Kang J, et al. Postoperative radiation therapy improves survivals of resected pathological stage ⅢA-N2 non-small cell lung cancer: a retrospective study of 1 434 cases from a single institution［J］. Int J Radiat Oncol Biol Phys, 2018, 102(3 Suppl): e685. ［20］ Shamp S, Biswas T. Post-operative radiation therapy (PORT) in resected non-small cell lung cancer (NSCLC): an updated population based analysis［J］. J Clin Oncol, 2018, 36(15 Suppl): 8522. DOI: 10.1200/JCO.2018.36.15_suppl.8522. ［21］ Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage ⅢA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial［J］. Lancet Respir Med, 2018, 6(11): 863-873. DOI: 10.1016/S2213-2600(18)30277-7. ［22］ Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-ⅢA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study［J］. Lancet Oncol, 2018, 19(1): 139-148. DOI: 10.1016/S1470-2045(17)30729-5. ［23］ Pennell NA, Neal JW, Chaft JE, et al. SELECT: a phase Ⅱ trial of adjuvant Erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer［J］. J Clin Oncol, 2019, 37(2): 97-104. DOI: 10.1200/jco.18.00131. ［24］ Huang Q, Li J, Sun Y, et al. Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant treatment for operable non-small cell lung cancer by a meta-analysis［J］. Chest, 2016, 149(6): 1384-1392. DOI: 10.1016/j.chest.2015.12.017. ［25］ Yuan Y, Huang Q, Gu C, et al. Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated metaanalysis［J］. J Thorac Dis, 2017, 9(12): 5314-5321. DOI: 10.21037/jtd.2017.12.58. ［26］ Bezjak A, Temin S, Franklin G, et al. Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: American society of clinical oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based clinical practice guideline［J］. J Clin Oncol, 2015, 33(18): 2100-2105. DOI: 10.1200/JCO.2014.59.2360. ［27］ Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC［J］. N Engl J Med, 2018, 379(24): 2342-2350. DOI: 10.1056/NEJMoa1809697. ［28］ Walraven I, Damhuis RA, Ten Berge MG, et al. Treatment variation of sequential versus concurrent chemoradiotherapy in stage Ⅲ non-small cell lung cancer patients in the Netherlands and Belgium［J］. Clin Oncol (R Coll Radiol), 2017, 29(11): e177-e185. DOI: 10.1016/j.clon.2017.07.012. ［29］ Vansteenkiste J, Crinò L, Dooms C, et al. 2nd ESMO consensus conference on lung cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up［J］. Ann Oncol, 2014, 25(8): 1462-1474. DOI: 10.1093/annonc/mdu089. ［30］ Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage ⅢA or ⅢB non-small-cell lung cancer (RTOG0617): a randomised, two-by-two factorial phase 3 study［J］. Lancet Oncol, 2015, 16(2): 187-199. DOI: 10.1016/S14702045(14)71207-0. ［31］ Doyen J, Poudenx M, Gal J, et al. Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: a TITE-CRM phase 1 trial［J］. Radiother Oncol, 2018, 127(2): 239-245. DOI: 10.1016/j.radonc.2018.03.024. ［32］ Hechtner M, Krause M, König J, et al. Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy-results of the randomized CHARTWEL trial［J］. Radiother Oncol, 2018, 126(2): 283-290. DOI: 10.1016/j.radonc.2017.12.005. ［33］ De Ruysscher D, Dingemans AC, Praag J, et al. Prophylactic cranial irradiation versus observation in radically treated stage Ⅲ non-small-cell lung cancer: a randomized phase Ⅲ NVALT-11/DLCRG-02 study［J］. J Clin Oncol, 2018, 36(23): 2366-2377. DOI: 10.1200/JCO.2017.77.5817. ［34］ Sun A, Hu C, Wong SJ, et al. Prophylactic cranial irradiation vs observation in patients with locally advanced non-small cell lung cancer: a long-term update of the NRG oncology/RTOG 0214 phase 3 randomized clinical trial［J］. JAMA Oncol, 2019. DOI: 10.1001/jamaoncol.2018.7220. ［35］ Palma DA, Olson RA, Harrow S, et al. Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial［J］. Int J Radiat Oncol Biol Phys, 2018, 102(3 Suppl): S3-S4. ［36］ Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial［J］. JAMA Oncol, 2018, 4(1): e173501. DOI: 10.1001/jamaoncol.2017.3501. ［37］ Gerber DE. Maintenance therapy for advanced lung cancer: who, what, and when?［J］. J Clin Oncol, 2013, 31(24): 2983-2990. DOI: 10.1200/jco.2012.48.5201. ［38］ Petty WJ, Urbanic JJ, Ahmed T, et al. Long-term outcomes of a phase 2 trial of chemotherapy with consolidative radiation therapy for oligometastatic non-small cell lung cancer［J］. Int J Radiat Oncol Biol Phys, 2018, 102(3): 527-535. DOI: 10.1016/j.ijrobp.2018.06.400. ［39］ Xu Q, Zhou F, Liu H, et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs［J］. J Thorac Oncol, 2018, 13(9): 1383-1392. DOI: 10.1016/j.jtho.2018.05.019. ［40］ Elamin YY, Gomez DR, Antonoff MB, et al. Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small-cell lung cancer (NSCLC)［J］. Clin Lung Cancer, 2019, 20(1): 43-47. DOI: 10.1016/j.cllc.2018.09.015.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[6]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[7]	Wang Kun, Zhou Zhongxin, Zang Qiwei. Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection [J]. Journal of International Oncology, 2024, 51(4): 198-203.
[8]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[9]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[10]	Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin. Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 137-142.
[11]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[12]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[13]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[14]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[15]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.